On 17 March 2020, FDA Circular No. 2020-007 was issued providing guidelines for the implementation of the use of electronic means of prescription for drugs for the benefit of individuals vulnerable to COVID-19. Thereafter, on 26 August 2020, FDA Circular No. 2020-007-A was issued to extend the validity of said Circular.
Considering that there are regular updates on the quarantine status of different localities, the validity of the provisions of this Circular should remain unaffected to ensure access to drugs for the benefit of vulnerable individuals to COVID-19.
Hence, FC No. 2020-007 shall be valid until 31 December 2020, regardless of the level of the imposed quarantine restriction, and subject to extension upon the review of this Office.
Attachement–>FDA-Circular-No.2020-007-B